Journal
EXPERIMENTAL DERMATOLOGY
Volume 20, Issue 11, Pages 894-898Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0625.2011.01346.x
Keywords
atopic dermatitis; itch; leukotriene B-4; scratching; sphingosylphosphorylcholine
Categories
Funding
- Ministry of Education, Culture, Sports, Science, and Technology, Japan [19790051, 22790063]
- Health, Labor, and Welfare Ministry, Japan
- ONO Medical Research Foundation
- Grants-in-Aid for Scientific Research [19790051, 22790063] Funding Source: KAKEN
Ask authors/readers for more resources
To elucidate the mechanisms of severe itch in atopic dermatitis, we investigated the role of leukotriene B-4, a potent itch mediator, in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions. Topical application of the BLT leukotriene B-4 receptor antagonist ONO-4057 inhibited spontaneous itch-related behaviour. The concentration of leukotriene B-4 was significantly increased in the lesional skin. The expression levels of 5-lipoxygenase were also elevated in the lesional skin, yet present throughout the epidermis of both healthy and lesional skin. These results suggest a role for leukotriene B-4 in chronic dermatitis-related itch. Sphingosylphosphorylcholine (SPC) was increased in the epidermis of the lesional skin. Moreover, intradermal injection of SPC elicited itch-related behaviours in healthy mice. Because SPC induces itch-related responses through the production of leukotriene B-4 in keratinocytes (J Invest Dermatol, 129, 2009, 2854), these results suggest that an increase in SPC induces leukotriene B-4-mediated itching in chronic dermatitis. BLT1 receptor and 5-lipoxygenase in the skin may be effective pharmacological targets for the treatment of itch in atopic dermatitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available